Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Boostrix: Phase III data

In an observer-blind, U.S. Phase III trial in 4,114 healthy subjects aged

Read the full 121 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE